Successful Treatment of Human Visceral Leishmaniasis Restores Antigen-Specific IFN-γ, but not IL-10 Production

PLoS Neglected Tropical Diseases

Volumn 10, Issue 3, 2016, Pages

  Adem, Emebet ^a   Tajebe, Fitsumbirhan ^a   Getahun, Mulusew ^a   Kiflie, Amare ^a   Diro, Ermias ^a   Hailu, Asrat ^b   Shkedy, Ziv ^c   Mengesha, Bewketu ^a   Mulaw, Tadele ^a   Atnafu, Saba ^a   Deressa, Tekalign ^a   Mathewos, Biniam ^a   Abate, Ebba ^a   Modolell, Manuel ^d   Munder, Markus ^e   Müller, Ingrid ^f   Takele, Yegnasew ^a,f   Kropf, Pascale ^f  

^a UNIVERSITY OF GONDAR   (Ethiopia)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c HASSELT UNIVERSITY   (Belgium)

^d MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ARGINASE; EDETIC ACID; GAMMA INTERFERON; HEPARIN; INTERLEUKIN 10; PAROMOMYCIN; STIBOGLUCONATE SODIUM; PARASITE ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; LEISHMANIA DONOVANI; LIMIT OF DETECTION; LOW DENSITY GRANULOCYTE; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYCLONAL ACTIVATION; PROMASTIGOTE; T LYMPHOCYTE; TREATMENT RESPONSE; UREA BLOOD LEVEL; VISCERAL LEISHMANIASIS; DRUG EFFECTS; ETHIOPIA; IMMUNOLOGY; INDIA; LEISHMANIASIS, VISCERAL; PATHOLOGY; SECRETION (PROCESS); TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, PROTOZOAN; ARGINASE; CROSS-SECTIONAL STUDIES; ETHIOPIA; GRANULOCYTES; HUMANS; INDIA; INTERFERON-GAMMA; INTERLEUKIN-10; LEISHMANIASIS, VISCERAL; MALE; T-LYMPHOCYTES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84962423965     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004468     Document Type: Article

References (34)

1. Bern C, Maguire JH, Alvar J, (2008) Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis2: e313. doi: 10.1371/journal.pntd.000031318958165
2. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS ONE7: e35671. doi: 10.1371/journal.pone.003567122693548
3. WHO (2010) Control of the leishmaniasis.
4. Nylen S, Sacks D, (2007) Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol28: 378–384. 17689290
5. Hailu A, van Baarle D, Knol GJ, Berhe N, Miedema F, et al. (2005) T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol117: 182–191. 16125466
6. Goto H, Prianti MG, (2009) Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo51: 241–246. 19893975
7. Kumar R, Nylen S, (2012) Immunobiology of visceral leishmaniasis. Front Immunol3: 251. doi: 10.3389/fimmu.2012.0025122912637
8. Bronte V, Zanovello P, (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol5: 641–654. 16056256
9. Rodriguez PC, Ochoa AC, (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev222: 180–191. doi: 10.1111/j.1600-065X.2008.00608.x18364002
10. Munder M, (2009) Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol158: 638–651. doi: 10.1111/j.1476-5381.2009.00291.x19764983
11. Takele Y, Abebe T, Weldegebreal T, Hailu A, Hailu W, et al. (2013) Arginase activity in the blood of patients with visceral leishmaniasis and HIV infection. PLoS Negl Trop Dis7: e1977. doi: 10.1371/journal.pntd.000197723349999
12. Abebe T, Takele T, Weldegebreal T, Cloke T, Closs E, et al. (2013) Arginase: a marker of disease status in patients with visceral leishmaniasis. PLoS NTD7: e2134.
13. Modolell M, Choi B-S, Ryan RO, Hancock M, Titus RG, et al. (2009) Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Neglected Tropical Diseases14: e480.
14. Gidwani K, Jones S, Kumar R, Boelaert M, Sundar S, (2011) Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for Leishmania donovani, a proof of concept study. PLoS Negl Trop Dis5: e1042. doi: 10.1371/journal.pntd.000104221526219
15. Singh OP, Gidwani K, Kumar R, Nylen S, Jones SL, et al. (2012) Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol19: 961–966. doi: 10.1128/CVI.00143-1222539471
16. Kumar R, Singh N, Gautam S, Singh OP, Gidwani K, et al. (2014) Leishmania specific CD4 T cells release IFNgamma that limits parasite replication in patients with visceral leishmaniasis. PLoS Negl Trop Dis8: e3198. doi: 10.1371/journal.pntd.000319825275531
17. Chulay JD, Bryceson AD, (1983) Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg32: 475–479. 6859397
18. Kropf P, Baud D, Marshall SE, Munder M, Mosley A, et al. (2007) Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. Eur J Immunol37: 935–945. 17330821
19. Banfi G, Salvagno GL, Lippi G, (2007) The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes. Clin Chem Lab Med45: 565–576. 17484616
20. Cloke T, (2011) Immunoregulation by arginase mediated L-arginine metabolism in HIV seropostive patients. London: Imperial College London.
21. Freitas M, Porto G, Lima JL, Fernandes E, (2008) Isolation and activation of human neutrophils in vitro. The importance of the anticoagulant used during blood collection. Clin Biochem41: 570–575. doi: 10.1016/j.clinbiochem.2007.12.02118226596
22. Nielsen H, (1985) Influence of five different anticoagulants on human blood monocyte isolation and functional activities. Acta Pathol Microbiol Immunol Scand C93: 49–52. 3925714
23. Cloke T, Garvery L, Choi BS, Abebe T, Hailu A, et al. (2010) Increased arginase activity correlates with disease severity in HIV seropositive patients. Journal of Infectious Diseases202: 374–385. doi: 10.1086/65373620575659
24. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, et al. (2010) A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol184: 3284–3297. doi: 10.4049/jimmunol.090219920164424
25. Fu J, Tobin MC, Thomas LL, (2014) Neutrophil-like low-density granulocytes are elevated in patients with moderate to severe persistent asthma. Ann Allergy Asthma Immunol113: 635–640 e632. doi: 10.1016/j.anai.2014.08.02425256681
26. Brandau S, Trellakis S, Bruderek K, Schmaltz D, Steller G, et al. (2011) Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol89: 311–317. doi: 10.1189/jlb.031016221106641
27. Gautam S, Kumar R, Maurya R, Nylen S, Ansari N, et al. (2011) IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis204: 1134–1137. doi: 10.1093/infdis/jir46121881130
28. Cillari E, Liew FY, Lo Campo P, Milano S, Mansueto S, et al. (1988) Suppression of IL-2 production by cryopreserved peripheral blood mononuclear cells from patients with active visceral leishmaniasis in Sicily. J Immunol140: 2721–2726. 3258620
29. Ho M, Koech DK, Iha DW, Bryceson AD, (1983) Immunosuppression in Kenyan visceral leishmaniasis. Clin Exp Immunol51: 207–214. 6839538
30. Ghose AC, Haldar JP, Pal SC, Mishra BP, Mishra KK, (1979) Phytohaemagglutinin-induced lymphocyte transformation test in Indian kala-azar. Trans R Soc Trop Med Hyg73: 725–726. 317188
31. Vanaerschot M, Decuypere S, Downing T, Imamura H, Stark O, et al. (2012) Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent. J Infect Dis206: 752–755. doi: 10.1093/infdis/jis42422753945
32. Khalil EA, Weldegebreal T, Younis BM, Omollo R, Musa AM, et al. (2014) Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial. PLoS Negl Trop Dis8: e2613. doi: 10.1371/journal.pntd.000261324454970
33. Gelanew T, Kuhls K, Hurissa Z, Weldegebreal T, Hailu W, et al. (2010) Inference of population structure of Leishmania donovani strains isolated from different Ethiopian visceral leishmaniasis endemic areas. PLoS Negl Trop Dis4: e889. doi: 10.1371/journal.pntd.000088921103373
34. Leish GENC, Wellcome Trust Case Control CFakiola M, Strange A, Cordell HJ, et al. (2013) Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat Genet45: 208–213. doi: 10.1038/ng.251823291585